Skip to main content
Fig. 3 | BMC Medical Imaging

Fig. 3

From: Dynamic contrast enhanced MRI of pulmonary adenocarcinomas for early risk stratification: higher contrast uptake associated with response and better prognosis

Fig. 3

DCE MRI of a 69 year-old female non-responder, smoker (15 pack years), adenocarcinoma right upper lobe (blue arrow), T3N1M1(Oss), received TKI, progression-free survival 117 days (progression by new lymph node metastases), overall survival 143 days. Pre-therapeutic strong uptake followed by post-therapeutic reduced uptake accompanied by early progression and short survival. Note: MR2 at day 11 due to scheduling delay, MR3 given additionally. Left: representative time points of DCE MRI pre-therapeutic (day 0) and post-therapeutic. Right: semiquantitative contrast enhancement curves (above absolute SI of tumor, middle relative contrast enhancement, below contrast normalized tumor to muscle SI).

Back to article page

BMC Medical Imaging

ISSN: 1471-2342

Contact us